|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||95.45 - 95.45|
|52-week range||88.75 - 112.65|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||17.23|
|Forward dividend & yield||3.86 (4.19%)|
|Ex-dividend date||05 May 2021|
|1y target est||N/A|
The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Actually, investors can have their cake and eat it too, balancing current income with principal appreciation.